Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01689519
Registration number
NCT01689519
Ethics application status
Date submitted
18/09/2012
Date registered
21/09/2012
Date last updated
2/05/2022
Titles & IDs
Public title
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
Query!
Scientific title
A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Query!
Secondary ID [1]
0
0
2012-003008-11
Query!
Secondary ID [2]
0
0
GO28141
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
coBRIM
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Malignant Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Vemurafenib
Treatment: Drugs - Cobimetinib
Active Comparator: Placebo + Vemurafenib - Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
Experimental: Cobimetinib + Vemurafenib - Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
Treatment: Drugs: Placebo
Placebo supplied as tablets
Treatment: Drugs: Vemurafenib
Vemurafenib supplied as tablets
Treatment: Drugs: Cobimetinib
Cobimetinib supplied as tablets
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival
Query!
Assessment method [1]
0
0
Progression-free survival was defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator using Response Evaluation Criteria in Solid Tumors v1.1, or death from any cause, whichever came first. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.
Query!
Timepoint [1]
0
0
Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Query!
Secondary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival was defined as the time from randomization until the date of death from any cause.
Query!
Timepoint [1]
0
0
Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Query!
Secondary outcome [2]
0
0
Percentage of Participants With an Objective Response
Query!
Assessment method [2]
0
0
An objective response was defined as a complete response or a partial response determined on two consecutive occasions = 4 weeks apart. Responses were determined by Response Evaluation Criteria in Solid Tumors v1.1. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter of target lesions.
Query!
Timepoint [2]
0
0
Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Query!
Secondary outcome [3]
0
0
Duration of Response
Query!
Assessment method [3]
0
0
Duration of response was defined as the time from first occurrence of a documented confirmed objective response until the time of disease progression, as determined by investigator review of tumor assessments using Response Evaluation Criteria in Solid Tumors v1.1 or death from any cause during the study. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.
Query!
Timepoint [3]
0
0
Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Query!
Eligibility
Key inclusion criteria
- Participants with histologically confirmed melanoma, either unresectable stage IIIc or
stage IV metastatic melanoma, as defined by the American Joint Committee on Cancer 7th
edition. Unresectability of stage IIIc disease must have confirmation from a surgical
oncologist
- Participants must be naïve to treatment for locally advanced unresectable or
metastatic disease (ie, no prior systemic anti-cancer therapy for advanced disease;
stage IIIc and IV). Prior adjuvant immunotherapy (including ipilimumab) is allowed
- Documentation of BRAF V600 mutation-positive status in melanoma tumor tissue (archival
or newly obtained tumor samples) using the cobas 4800 BRAF V600 mutation test
- Measurable disease per RECIST v1.1
- Eastern Clinical Oncology Group performance status of 0 or 1
- Consent to provide archival for biomarker analyses
- Consent to undergo tumor biopsies for biomarker analyses
- Life expectancy greater than or equal to (=) 12 weeks
- Adequate hematologic and end organ function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of prior rapidly accelerated fibrosarcoma or mitogen-activated protein kinase
pathway inhibitor treatment
- Palliative radiotherapy within 14 days prior to the first dose of study treatment
- Major surgery or traumatic injury within 14 days prior to first dose of study
treatment
- Active malignancy other than melanoma that could potentially interfere with the
interpretation of efficacy measures. Participants with a previous malignancy within
the past 3 years are excluded except for participants with resected basal cell
carcinoma or squamous cell carcinoma of the skin, melanoma in-situ, carcinoma in-situ
of the cervix, and carcinoma in-situ of the breast
- History of or evidence of retinal pathology on ophthalmological examination that is
considered a risk factor for neurosensory retinal detachment, retinal vein occlusion,
or neovascular macular degeneration
- Uncontrolled glaucoma with intraocular pressure
- Serum cholesterol = Grade 2
- Hypertriglyceridemia = Grade 2
- Hyperglycemia (fasting) = Grade 2
- History of clinically significant cardiac dysfunction
- Participants with active central nervous system (CNS) lesions (including carcinomatous
meningitis) are excluded. However, participants are eligible if:
1. All known CNS lesions have been treated with stereotactic therapy or surgery, AND
2. There has been no evidence of clinical and radiographic disease progression in
the CNS for = 3 weeks after radiotherapy or surgery
- Current severe, uncontrolled systemic disease
- History of malabsorption or other condition that would interfere with absorption of
study drugs
- Pregnant, lactating, or breast feeding women
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/01/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
21/07/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
495
Query!
Recruitment in Australia
Recruitment state(s)
NSW,NT,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Chris O'Brien Lifehouse - Camperdown
Query!
Recruitment hospital [2]
0
0
Lake Macquarie Private Hospital - Gateshead
Query!
Recruitment hospital [3]
0
0
Lismore Base Hospital; Cancer Care & Haematology Unit - Lismore
Query!
Recruitment hospital [4]
0
0
Melanoma Institute Australia - North Sydney
Query!
Recruitment hospital [5]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [6]
0
0
Royal Darwin Hospital - Casuarina
Query!
Recruitment hospital [7]
0
0
Greenslopes Private Hospital - Greenslopes
Query!
Recruitment hospital [8]
0
0
Royal Brisbane and Women's Hospital - Herston
Query!
Recruitment hospital [9]
0
0
Royal Adelaide Hospital; Hepatology - Adelaide
Query!
Recruitment hospital [10]
0
0
Ashford Cancer Centre - Ashford SA
Query!
Recruitment hospital [11]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [12]
0
0
Launceston General Hospital; Gastroenterology Research - Launceston
Query!
Recruitment hospital [13]
0
0
Peninsula and South Eastern Haematology and Oncology Group - Frankston
Query!
Recruitment hospital [14]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [15]
0
0
Peter MacCallum Cancer Centre-East Melbourne - Melbourne
Query!
Recruitment hospital [16]
0
0
The Alfred Hospital - Prahan
Query!
Recruitment hospital [17]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2290 - Gateshead
Query!
Recruitment postcode(s) [3]
0
0
2480 - Lismore
Query!
Recruitment postcode(s) [4]
0
0
2060 - North Sydney
Query!
Recruitment postcode(s) [5]
0
0
2050 - Woolloongabba
Query!
Recruitment postcode(s) [6]
0
0
0811 - Casuarina
Query!
Recruitment postcode(s) [7]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [8]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [9]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [10]
0
0
5035 - Ashford SA
Query!
Recruitment postcode(s) [11]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [12]
0
0
7250 - Launceston
Query!
Recruitment postcode(s) [13]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [14]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [15]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [16]
0
0
3181 - Prahan
Query!
Recruitment postcode(s) [17]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Hampshire
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Rhode Island
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Linz
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
St. Pölten
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Wien
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Bruxelles
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Edegem
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Hasselt
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Liège
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Roeselare
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
British Columbia
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Brno
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Hradec Kralove
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Olomouc
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Ostrava - Poruba
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Pardubice
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Prague
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Praha 2
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Praha
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Bordeaux
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Boulogne Billancourt
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Clermont Ferrand cedex 1
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Dijon
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
La Tronche
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Lille
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Marseille
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Montpellier
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Nantes
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Nice
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Pierre Benite
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Reims
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Rennes
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Bochum
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Buxtehude
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Dresden
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Erfurt
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Essen
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Freiburg
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Gera
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Göttingen
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Hamburg
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Hannover
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Heidelberg
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Kiel
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Koeln
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Mainz
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Mannheim
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Muenster
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
München
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Regensburg
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Tuebingen
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Würzburg
Query!
Country [67]
0
0
Hungary
Query!
State/province [67]
0
0
Budapest
Query!
Country [68]
0
0
Hungary
Query!
State/province [68]
0
0
Gyula
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Pecs
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Szeged
Query!
Country [71]
0
0
Israel
Query!
State/province [71]
0
0
Beer Sheva
Query!
Country [72]
0
0
Israel
Query!
State/province [72]
0
0
Haifa
Query!
Country [73]
0
0
Israel
Query!
State/province [73]
0
0
Jerusalem
Query!
Country [74]
0
0
Israel
Query!
State/province [74]
0
0
Petach Tikva
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Ramat Gan
Query!
Country [76]
0
0
Israel
Query!
State/province [76]
0
0
Tel Aviv
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Campania
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Emilia-Romagna
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Lazio
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Liguria
Query!
Country [81]
0
0
Italy
Query!
State/province [81]
0
0
Lombardia
Query!
Country [82]
0
0
Italy
Query!
State/province [82]
0
0
Puglia
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Toscana
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Veneto
Query!
Country [85]
0
0
Netherlands
Query!
State/province [85]
0
0
Amsterdam
Query!
Country [86]
0
0
Netherlands
Query!
State/province [86]
0
0
Leiden
Query!
Country [87]
0
0
Netherlands
Query!
State/province [87]
0
0
Maastricht
Query!
Country [88]
0
0
New Zealand
Query!
State/province [88]
0
0
Auckland
Query!
Country [89]
0
0
New Zealand
Query!
State/province [89]
0
0
Hamilton
Query!
Country [90]
0
0
Norway
Query!
State/province [90]
0
0
Oslo
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
Barnaul
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Moscow
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Omsk
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Pyatigorsk
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
LA Coruña
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Navarra
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Sevilla
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Barcelona
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Madrid
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Valencia
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Zaragoza
Query!
Country [102]
0
0
Sweden
Query!
State/province [102]
0
0
Jönköping
Query!
Country [103]
0
0
Sweden
Query!
State/province [103]
0
0
Lund
Query!
Country [104]
0
0
Sweden
Query!
State/province [104]
0
0
Mölnlycke
Query!
Country [105]
0
0
Sweden
Query!
State/province [105]
0
0
Uppsala
Query!
Country [106]
0
0
Switzerland
Query!
State/province [106]
0
0
Bern
Query!
Country [107]
0
0
Switzerland
Query!
State/province [107]
0
0
Chur
Query!
Country [108]
0
0
United Kingdom
Query!
State/province [108]
0
0
Bristol
Query!
Country [109]
0
0
United Kingdom
Query!
State/province [109]
0
0
Cambridge
Query!
Country [110]
0
0
United Kingdom
Query!
State/province [110]
0
0
Cardiff
Query!
Country [111]
0
0
United Kingdom
Query!
State/province [111]
0
0
Edinburgh
Query!
Country [112]
0
0
United Kingdom
Query!
State/province [112]
0
0
Glasgow
Query!
Country [113]
0
0
United Kingdom
Query!
State/province [113]
0
0
Liverpool
Query!
Country [114]
0
0
United Kingdom
Query!
State/province [114]
0
0
London
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
Newcastle upon Tyne
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Nottingham
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Southampton
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Truro
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Wolverhampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared
with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients
with unresectable locally advanced or metastatic melanoma, as measured by progression-free
survival (PFS), assessed by the study site investigator.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01689519
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01689519
Download to PDF